YONKERS, N.Y., June 22, 2004 (PRIMEZONE) -- Advanced Viral Research Corp. (OTCBB:ADVR) announced today an investor conference call will be held at 4:00 p.m. Eastern Standard Time on Wednesday, July 21st 2004.
Dr. Hawkins will discuss the ASCO presentation and the significance of the data from Israel. The conference call is expected to last one hour and will include a brief question and answer period.
ADVR invites all interested parties to participate in the conference call. Participants will be able to access via the Internet or by dialing in to a conference bridge. For those who cannot participate on the live call ADVR will have the call available for replay on the conference line or on www.adviral.com the following day.
Instructions for hearing the conference call:
Call 1-800-901-5231 in the United States or Canada or Call 1- 617-786-2961 internationally Pin Code: 61291146 Instructions for hearing the conference call replayed: Dates available July 21st-28th Call 1-888-286-8010 in the United States or Canada or Call 1-617-801-6888 Pin Code: 61291146
ADVR's AVR118 represents a biopolymer that possesses novel immunomodulator activity. This peptide-nucleic acid complex, which to date has demonstrated a very favorable safety profile, appears to stimulate the proinflammatory responses required to combat viral infections such as AIDS and human papillomavirus and to dampen aberrant autoimmune-type inflammatory responses, such as occur in patients with rheumatoid arthritis. AVR118 is in clinical trials in Israel for the treatment of cachexia (body wasting) in patients with AIDS.
For further information regarding Advanced Viral Research Corp., please visit our website at www.adviral.com. Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for viral and other diseases.
Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 (Product R) is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company or that if completed, clinical trials performed outside the United States will assist the Company in obtaining FDA or other regulatory approval. . The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.